[ET Net News Agency, 28 July 2021] Macquarie initiates coverage of Hutchmed (00013)
with a target price of HK$83.31 and an "outperform" rating.
The research house said with cash of over US$1bn to support acquisitions, it expects a
deeper pipeline could strengthen investor confidence in upcoming new launches, balancing
dependence on its strong discovery capability and mitigating policy risks on existing
products. (RC)